Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments

Gore, M. O., McGuire, D. K. · 2011 · European Heart Journal

Abstract

This editorial refers to ‘Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study’†, by T.K. Schramm et al., on page 1900 As illustrated most recently by the controversy surrounding the myocardial infarction risk associated with rosiglitazone,1 substantial uncertainty remains regarding the effects of different glucose-lowering drug classes and, importantly, different drugs within each class on cardiovascular (CV) risk and mortality outcomes in patients with type 2 diabetes (T2DM). In the setting of the ongoing proliferation of anti-hyperglycaemic therapeutic classes and formulations with myriad therapeutic options for the treatment of T2DM presently available,2 this uncertainty has prompted regulatory agencies in both Europe and the USA to reassess the approval process for new T2DM medications, with changes focused primarily on excluding with a specified degree of statistical certainty incremental CV risk prior to new drug approval.3 Long-term randomized clinical outcome trials with both new and presently available medications are recommended, but not mandated. In the absence of definitive CV risk assessment from randomized trials for presently available drug classes and individual drugs within each class, critical analyses of existing databases are both imperative and informative.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehr019

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. Goldner, 1971, JAMA, 218, 1400, 10.1001/jama.1971.03190220020005 · doi:10.1001/jama.1971.03190220020005 · Paper page

Cited by

See all 23

Metadata

Authors
Gore, M. O., & McGuire, D. K.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
McGuire, D. K.
Venue
European Heart Journal
Published
2011-04-06
Volume
32
Issue
15
Pages
1832-1834
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2003077957
Cited by
23
References
20
Citations by year
2023: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 4 · 2013: 2 · 2012: 3
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, cardiovascular risk, drug class effect, insulin secretagogues, metformin, rosiglitazone, mortality, drug approval regulation
MeSH terms
Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Hypoglycemic Agents, Insulin, Metformin, Myocardial Infarction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. https://app.cochat.ai/papers/10.1093/eurheartj/ehr019
The paper
Gore, M. O., & McGuire, D. K. (2011). Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. European Heart Journal. https://doi.org/10.1093/eurheartj/ehr019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.